Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Medical Officer

SVP Finance, CFO

SVP & Chief Commercial Officer

Chief Executive Officer

SVP, Chief Business Officer

SVP of Research, CSO

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-29	Premium	acquired	Premium	Premium	Premium	-
2024-03-29	Premium	acquired	Premium	Premium	Premium	-
2024-03-29	Premium	acquired	Premium	Premium	Premium	-
2023-12-29	Premium	acquired	Premium	Premium	Premium	-
2023-12-29	Premium	acquired	Premium	Premium	Premium	-
2023-12-29	Premium	acquired	Premium	Premium	Premium	-
2023-09-30	Premium	acquired	Premium	Premium	Premium	-
2023-09-30	Premium	acquired	Premium	Premium	Premium	-
2023-09-30	Premium	acquired	Premium	Premium	Premium	-
2023-09-22	Premium	bought	Premium	Premium	Premium	Chief Medical Officer
2023-09-21	Premium	bought	Premium	Premium	Premium	Chief Medical Officer
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-05-17	Premium	sold	Premium	Premium	Premium	SVP Finance, CFO
2023-05-10	Premium	bought	Premium	Premium	Premium	-
2023-05-08	Premium	bought	Premium	Premium	Premium	SVP & Chief Commercial Officer
2023-02-24	Premium	bought	Premium	Premium	Premium	-
2023-02-23	Premium	bought	Premium	Premium	Premium	-
2023-02-22	Premium	bought	Premium	Premium	Premium	-
2023-02-21	Premium	bought	Premium	Premium	Premium	-
2023-02-17	Premium	bought	Premium	Premium	Premium	-
2023-02-16	Premium	bought	Premium	Premium	Premium	-
2023-02-15	Premium	bought	Premium	Premium	Premium	-
2023-02-09	Premium	bought	Premium	Premium	Premium	-
2023-01-27	Premium	acquired	Premium	Premium	Premium	-
2023-01-26	Premium	sold	Premium	Premium	Premium	-

GLYC - GlycoMimetics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for GLYC